Regeneron's Eylea HD launch is being squeezed by Roche's Vabysmo and incoming aflibercept biosimilars. Patent litigation against Amgen and Samsung Bioepis biosimilars looks increasingly tenuous after recent court rulings. Dupixent remains a crown jewel but the partnership economics favor Sanofi long-term. Pipeline depth is thin relative to large-cap peers.
Thesis reviewed May 29, 2026
Regeneron Pharmaceuticals Inc. is headquartered in United States, which is currently showing moderate signals.
🇺🇸United States48EARLYView United States risk detail →💊Pharma0NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| AZN | AstraZeneca PLC | 50 | +11% | ↓0% | EARLY |
| LLY | Eli Lilly and Company | 50 | +24% | ↓0% | EARLY |
| GSK | GSK plc | 50 | +8% | ↓0% | NEUTRAL |
| SNY | Sanofi | 50 | +14% | ↓0% | EARLY |
| NVO | Novo Nordisk A/S | 50 | +15% | ↓0% | EARLY |
| RDY | Dr Reddy's Laboratories Ltd | 50 | +7% | ↓0% | NEUTRAL |
| TAK | Takeda Pharmaceutical Company Limited | 50 | +10% | ↓0% | NEUTRAL |
Investors who hold REGN may also have indirect exposure through these country funds.
Federal court denies Regeneron preliminary injunction on aflibercept biosimilar
Eylea HD share gains plateau as Vabysmo extends durability claim
Two more biosimilar aflibercept launches expected Q3 2026
Estimates · Yahoo Finance · Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Julia LetlowLA | R | Buy | $1k–$15k | Feb 12, 26 | -17.5% |
| Jonathan JacksonIL | D | Buy | Unknown amount | Nov 13, 24 | -16.3% |
| Jonathan JacksonIL | D | Sell | $1k–$15k | Nov 1, 24 | -16.3% |
| Josh GottheimerNJ | D | Sell | $1k–$15k | Nov 29, 24 | -19.3% |
| Josh GottheimerNJ | D | Sell | $1k–$15k | Nov 19, 24 | -19.3% |
| Greg LandsmanOH | D | Buy | $1k–$15k | Oct 15, 24 | -20.8% |
| Josh GottheimerNJ | D | Sell | $1k–$15k | Oct 23, 24 | -24.1% |
| Josh GottheimerNJ | D | Sell | $1k–$15k | Jul 1, 24 | -47.3% |
| Greg LandsmanOH | D | Buy | $1k–$15k | Aug 11, 23 | -46.4% |